Pharmacokinetics of Hizentra at Weekly vs. Biweekly Dosing Regimens

Pharmacokinetics (PK) of the 20% subcutaneous immunoglobulin (SCIG) Hizentra in patients with primary immune deficiency (PID) is well established for weekly dosing. However, PK data of SCIG infusions every 2 weeks (biweekly) are not available